• Unlike in humans hepatic expression of FGF increases

  2024-01-04

  

  Unlike in humans, hepatic expression of FGF21 increases in mice consuming KD and is a necessary mediator of the physiologic adaptations to the diet. FGF21 knockout (KO) mice gain, rather than lose weight on the diet [6]. FGF21 also activates BAT in part by increasing SNS drive [3,7]. In addition, th

• While HTPCs are not immune

  2024-01-04

  

  While HTPCs are not immune cells, they produce IL-6, MCP-1 and other immunologically relevant factors (Mayer et al., 2016). Our results demonstrated that epinephrine and phenylephrine increased the mRNA expression levels of COX-2, IL-6 and MCP-1 in HTPCs without affecting the mRNA expression level o

• br Adenosine receptors and the adaptive

  2024-01-04

  

  Adenosine receptors and the adaptive immunity T lymphocytes are responsible for the cell-mediated immune response [95]. These cells can be stimulated by the presentation of antigenic moieties by APCs, such as dendritic cells or macrophages [96]. The presentation of antigenic molecules on the APC

• hyPerFUsion™ high-fidelity PCR Kit br Materials and methods

  2024-01-04

  

  Materials and methods Results Discussions Diabetes is mainly divided into Type 1 diabetes and Type 2 diabetes [16]. Type 2 diabetes, featured by insulin resistance, results from environmental factors and poor eating habits [2]. Type 2 diabetes accounts for more than 95% of the diabetic pati

• br Conclusion br Conflicts of interest br Compliance with

  2024-01-04

  

  Conclusion Conflicts of interest Compliance with ethical standards Introduction Tuberculosis is one of the leading causes of morbidity and mortality, amongst infectious diseases. India is a high burden country for Tuberculosis. Caused by Mycobacterium tuberculosis, it AR-12 can present a

• The c C T mutation identified in subject K

  2024-01-04

  

  The c.286C>T mutation identified in subject K20-1 was also reported in other ethnic groups, including Brazilian, French-Canadian, Italian, and Arabs from the United Arab Emirates [20], [21], [22], whereas c.318A>G mutation in subjects K10-1 was previously reported in Asian and Caucasians [13], [23],

• Tumor suppressor ARF regulates the activity of p by inhibiti

  2024-01-03

  

  Tumor suppressor ARF regulates the activity of p53 by inhibiting the functions of Mdm2. ARF is induced by hyperproliferative signals emanating from oncogenic Ras, overexpressed c-myc, and from deregulated E2F . ARF prevents p53 degradation and leads to increased p53 function by sequestering Mdm2 to

• br Material and methods br

  2024-01-03

  

  Material and methods Results Discussion This study explores the hypothesis that ASK1, via transcriptional upregulation by E2F1, molecularly defines AT that supports a dys-metabolic obese phenotype in humans. We demonstrate associations between increased visceral-AT ASK1 expression and multi

• br Experimental All reagents were analytical grade and were

  2024-01-03

  

  Experimental All reagents were analytical grade and were used without further purification. The morphology was characterized using a field emission scanning electron microscope (Philips XL-30 FESEMFeSEM, ZEISS SUPRA 40VP, Germany). The hydrogel sample used for SEM analysis was freeze dried. All e

• tetracycline hcl Some of previous immunohistochemical studie

  2024-01-03

  

  Some of previous immunohistochemical studies have compared the levels of AR expression in low-grade versus high-grade and/or non-muscle-invasive versus muscle-invasive tumors. There was a significant or marginal decrease (Boorjian et al., 2004, Miyamoto et al., 2012b, Rau et al., 2011, Shyr et al.,

• ERAP has been crystallized in

  2024-01-03

  

  ERAP1 has been crystallized in two different conformations, wherein the C-terminal domain IV is either closely interacting with domains I/II and enclosing the active site (termed ‘closed’), or is rotated away in a hinge motion which exposes the active site (‘open’). This large motion correlates with

• Lorlatinib is an orally active

  2024-01-03

  

  Lorlatinib is an orally active brain penetrant cyclic 2-aminopyridine derivative that is a type I½ B ALK inhibitor (Fig. 5F) [61]. This medicinal is an effective antagonist against the more common L1196M and G1269A crizotinib-resistant mutations as well as the less common T1151Ins, L1152R, C1156Y, F

• br Introduction Clinical manifestations of Alzheimer

  2024-01-03

  

  Introduction Clinical manifestations of Alzheimer's disease (AD) are mainly characterized by progressive intellectual deterioration, memory impairment, cognitive impairment, and psychiatric symptoms. The pathogenesis of AD remains unclear, mainly containing genetic factors, neurotransmitter disor

• br Material and methods br

  2024-01-03

  

  Material and methods Results Discussion To develop a novel regenerative and/or neuroprotective therapy for optic neuropathy, including glaucoma, numerous studies have tested new candidates favorable to RGC survival and axon regeneration. Among the many candidate drugs, AdoR modulators are o

• The potential use of derivatives belonging to this series as

  2024-01-03

  

  The potential use of derivatives belonging to this series as therapeutic agents mostly depends on their pharmacokinetics and pharmacodynamics. The pharmacokinetic phase includes absorption, distribution, metabolism and excretion (ADME) of the studied compounds. Therefore, preliminary data for theore

16079 records 219/1072 page Previous Next First page 上5页 216217218219220 下5页 Last page